Research In Motion Limited(NASDAQ:RIMM): Jefferies lowered its estimates and price target for Research in Motion as it sees a greater than 50% chance that the company negatively pre-announces the February quarter. The firm believes sales of both RIM’s low-end and higher-end phones continue to be challenged and feels FY13 consensus estimates for the company are too high. Jefferies lowered its FY13 earnings estimate for RIM to $1.87, below the consensus of $3.07, dropped its price target for shares to $12 from $15, and reiterates an Underperform rating on the stock.
Advanced Micro Devices, Inc.(NYSE:AMD): Canaccord said AMD’s purchase of SeaMicro accelerates its growth in micro-servers. The firm reiterates its Buy rating and $9 price target.
Regeneron Pharmaceuticals, Inc.(NASDAQ:REGN): Jefferies learned that due to the successful launch of Regeneron’s (NASDAQ:REGN) Eylea, Roche (RHHBY) recently lowered the price per injection for Lucentis to $1,903 from $1,950, which remains below Eylea’s price of $1,850 per injection. Jefferies believes the price decrease along with a rebate to high volume centers could close the price gap between the two drugs. However, the firm believes Eylea has an on-label dosing advantage and points out that a retina specialist it spoke to expects 40% of his patients will be treated with Eylea by year-end 2012 despite the Lucentis price decrease. Jefferies keeps a Buy rating on Regeneron shares with a $127 price target.
JDS Uniphase Corporation(NASDAQ:JDSU): Credit Suisse recommends buying JDSU (NASDAQ:JDSU) on weakness related to Finisar’s (NASDAQ:FNSR) weak outlook. The firm said delayed telecom-related optical components demand discussed by Finisar is already reflected in JDSU’s model. Shares of JDSU are Outperform rated with a $17 price target.
Amarin Corporation plc(NASDAQ:AMRN): Leerink notes that Amarin shares sold off yesterday afternoon after the U.S. Patent and Trademark Office posted two non-final rejections related to the company’s ‘889 and ‘408 patent applications. Leerink thinks the non-final rejections may contain resolvable items and continues to see value in the stock. The firm believes Amarin will ultimately obtain one or more additional patents and reiterates an Outperform rating on the stock post the company’s Q4 results.
Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.
To contact the reporter on this story: Derek Hoffman at email@example.com
To contact the editor responsible for this story: Damien Hoffman at firstname.lastname@example.org